Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ENTX NASDAQ:FBRX NASDAQ:FNCH NASDAQ:TCRX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeENTXEntera Bio$1.84+0.3%$2.00$1.41▼$2.79$83.18M1.4666,881 shs9,071 shsFBRXForte Biosciences$11.45-8.3%$10.28$4.11▼$28.68$82.16M2.97173,240 shs113,360 shsFNCHFinch Therapeutics Group$12.75-1.9%$13.26$1.27▼$15.85$20.88M1.212,149 shs1,741 shsTCRXTScan Therapeutics$1.84$1.49$1.02▼$7.89$104.13M0.97408,742 shs231,710 shsInvesting Strategies To Help Grow Your Retirement IncomeNeed to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceENTXEntera Bio+0.27%-5.90%-13.85%+8.58%+1.94%FBRXForte Biosciences-8.25%-17.09%-6.53%+118.10%+56,027.45%FNCHFinch Therapeutics Group-1.92%-2.49%-4.76%+2.82%+858.65%TCRXTScan Therapeutics0.00%+21.85%+8.88%+48.39%-69.84%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationENTXEntera Bio2.289 of 5 stars3.55.00.00.00.60.80.0FBRXForte Biosciences3.3749 of 5 stars3.54.00.00.03.31.70.6FNCHFinch Therapeutics Group1.1444 of 5 stars0.03.00.00.02.91.70.6TCRXTScan Therapeutics2.643 of 5 stars3.51.00.00.02.03.30.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceENTXEntera Bio 3.00Buy$10.00444.96% UpsideFBRXForte Biosciences 3.00Buy$61.00432.75% UpsideFNCHFinch Therapeutics Group 0.00N/AN/AN/ATCRXTScan Therapeutics 3.00Buy$7.80323.91% UpsideCurrent Analyst Ratings BreakdownLatest FNCH, FBRX, ENTX, and TCRX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/24/2025FBRXForte BiosciencesChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$61.005/7/2025TCRXTScan TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$15.00 ➝ $10.005/6/2025TCRXTScan TherapeuticsWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform$7.00(Data available from 7/11/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookENTXEntera Bio$180K463.34N/AN/A$0.23 per share7.98FBRXForte BiosciencesN/AN/AN/AN/A$8.21 per shareN/AFNCHFinch Therapeutics GroupN/AN/AN/AN/A$14.25 per shareN/ATCRXTScan Therapeutics$4.42M23.55N/AN/A$4.26 per share0.43Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateENTXEntera Bio-$9.54M-$0.26N/AN/AN/A-4,525.11%-95.10%-82.77%8/8/2025 (Estimated)FBRXForte Biosciences-$35.48M-$16.29N/AN/AN/AN/A-149.15%-114.25%8/13/2025 (Estimated)FNCHFinch Therapeutics Group-$74.75M-$8.82N/A∞N/AN/A-69.14%-26.92%N/ATCRXTScan Therapeutics-$127.50M-$1.09N/AN/AN/A-2,974.08%-55.76%-36.56%8/11/2025 (Estimated)Latest FNCH, FBRX, ENTX, and TCRX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/8/2025Q2 2025ENTXEntera Bio-$0.11N/AN/AN/AN/AN/A5/15/2025Q1 2025FBRXForte Biosciences-$0.89-$1.37-$0.48-$1.37N/AN/A5/12/2025Q1 2025TCRXTScan Therapeutics-$0.28-$0.26+$0.02-$0.26$1.62 million$2.17 million5/9/2025Q1 2025ENTXEntera Bio-$0.07-$0.06+$0.01-$0.06N/A$0.04 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthENTXEntera BioN/AN/AN/AN/AN/AFBRXForte BiosciencesN/AN/AN/AN/AN/AFNCHFinch Therapeutics GroupN/AN/AN/AN/AN/ATCRXTScan TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioENTXEntera BioN/A13.0713.07FBRXForte BiosciencesN/A5.225.22FNCHFinch Therapeutics GroupN/A3.873.87TCRXTScan Therapeutics0.158.558.55Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipENTXEntera Bio14.11%FBRXForte Biosciences77.63%FNCHFinch Therapeutics Group21.77%TCRXTScan Therapeutics82.83%Insider OwnershipCompanyInsider OwnershipENTXEntera Bio10.38%FBRXForte Biosciences5.90%FNCHFinch Therapeutics Group44.90%TCRXTScan Therapeutics4.35%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableENTXEntera Bio2045.45 million40.73 millionOptionableFBRXForte Biosciences56.58 million6.20 millionOptionableFNCHFinch Therapeutics Group1901.61 million885,000No DataTCRXTScan Therapeutics10056.59 million54.13 millionNot OptionableFNCH, FBRX, ENTX, and TCRX HeadlinesRecent News About These CompaniesTScan Therapeutics, Inc. (NASDAQ:TCRX) Receives Consensus Recommendation of "Buy" from AnalystsJuly 9 at 2:26 AM | marketbeat.comTscan Therapeutics Inc News (TCRX) - Investing.comJuly 9 at 2:16 AM | investing.comTScan Therapeutics (NASDAQ:TCRX) Stock Price Down 4% - Time to Sell?July 8 at 3:32 AM | marketbeat.comTScan Therapeutics, Inc. (NASDAQ:TCRX) Receives Average Recommendation of "Buy" from BrokeragesJune 14, 2025 | marketbeat.comWall Street Zen Downgrades TScan Therapeutics (NASDAQ:TCRX) to SellJune 14, 2025 | marketbeat.comTScan Therapeutics Announces Upcoming Presentation at the Jefferies Global Healthcare ConferenceMay 28, 2025 | globenewswire.comLynx1 Capital Management Lp Acquires 1,200,000 Shares of TScan Therapeutics, Inc. (NASDAQ:TCRX) StockMay 22, 2025 | insidertrades.comWhat Analysts Are Saying About TScan Therapeutics StockMay 9, 2025 | nasdaq.com3TCRX : What Analysts Are Saying About TScan Therapeutics StockMay 7, 2025 | benzinga.comTScan Therapeutics, Inc. (TCRX) Reports Q1 Loss, Tops Revenue EstimatesMay 6, 2025 | zacks.comTScan Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate UpdateMay 6, 2025 | globenewswire.comTScan Therapeutics Announces Abstract Acceptance for Poster Presentation at ASGCT 28th Annual MeetingApril 30, 2025 | nasdaq.comTScan Therapeutics Announces Upcoming Presentation at the American Society of Gene and Cell Therapy 28th Annual MeetingApril 28, 2025 | globenewswire.comWhy TScan Therapeutics, Inc.’s (TCRX) Stock Is Up 9.62%April 17, 2025 | aaii.comANeedham Sticks to Its Buy Rating for TScan Therapeutics (TCRX)April 9, 2025 | markets.businessinsider.comWhy TScan Therapeutics, Inc.’s (TCRX) Stock Is Up 17.27%April 8, 2025 | aaii.comATScan Therapeutics to Participate in the 24th Annual Needham Virtual Healthcare ConferenceMarch 31, 2025 | globenewswire.comTScan Therapeutics appoints Camiolo as SVP, Market AccessMarch 27, 2025 | markets.businessinsider.comTScan Therapeutics Appoints Commercial Leader Stephen Camiolo as Senior Vice President, Market AccessMarch 27, 2025 | globenewswire.comWhy TScan Therapeutics, Inc.’s (TCRX) Stock Is Down 10.92%March 18, 2025 | aaii.comATScan Therapeutics assumed with an Overweight at Morgan StanleyMarch 14, 2025 | markets.businessinsider.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeFNCH, FBRX, ENTX, and TCRX Company DescriptionsEntera Bio NASDAQ:ENTX$1.84 +0.01 (+0.27%) Closing price 07/10/2025 03:50 PM EasternExtended Trading$1.84 +0.01 (+0.54%) As of 08:00 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Entera Bio Ltd., a clinical-stage company, focuses on the development and commercialization of orally delivered peptide and protein therapeutics for unmet medical needs. The company's product candidates include the EB612, which is in Phase II clinical trials for the treatment of hypoparathyroidism; and EB613 that has completed Phase II clinical trials for the treatment of osteoporosis, as well as is in Phase I clinical trials for the treatment of stress fractures. Its other product candidate is GLP-2, which is in preclinical trial for the treatment of short bowl syndrome; and OXM for the treatment of obesity and metabolic diseases. The company has a research collaboration and license agreement with the Amgen Inc. for the development and discovery of clinical candidates in the field of inflammatory disease and other serious illnesses. Entera Bio Ltd. was incorporated in 2009 and is based in Jerusalem, Israel.Forte Biosciences NASDAQ:FBRX$11.45 -1.03 (-8.25%) Closing price 07/10/2025 04:00 PM EasternExtended Trading$11.46 +0.01 (+0.04%) As of 07/10/2025 04:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Forte Biosciences, Inc. operates as a biopharmaceutical company in the United States. The company is developing FB-102 program that addresses various autoimmune diseases, such as graft-versus-host disease, and vitiligo and alopecia areata. Forte Biosciences, Inc. is headquartered in Dallas, Texas.Finch Therapeutics Group NASDAQ:FNCH$12.75 -0.25 (-1.92%) As of 07/10/2025 01:49 PM EasternFinch Therapeutics Group, Inc., a clinical-stage microbiome therapeutics company, develops a novel class of orally administered biological drugs in the United States. The company develops FIN-211, a microbiome candidate designed to address the gastrointestinal and behavioral symptoms of autism spectrum disorder; and FIN-524 for the prevention, diagnosis, theragnosis or treatment of diseases in humans, including ulcerative colitis; FIN-525 for the treatment of Crohn's disease; and other microbiome product candidates. The company has collaboration and license agreements with Takeda Pharmaceutical Company Limited; and license agreements with Skysong Innovations LLC, OpenBiome, Arizona State University, and University of Minnesota. Finch Therapeutics Group, Inc. was incorporated in 2014 and is based in Boston, Massachusetts.TScan Therapeutics NASDAQ:TCRX$1.84 0.00 (0.00%) Closing price 07/10/2025 04:00 PM EasternExtended Trading$1.90 +0.06 (+3.53%) As of 09:01 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.TScan Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops T cell receptor-engineered T cell (TCR-T) therapies for the treatment of patients with cancer in the United States. The company's lead product candidates include TSC-100 and TSC-101 that is in Phase I clinical trial for the treatment of patients with hematologic malignancies to eliminate residual disease and prevent relapse after allogeneic hematopoietic cell transplantation. It also develops TSC-200, TSC-201, TSC-203, and TSC-204, which are in Phase 1 clinical trial, for the treatment of solid tumors; and TSC-202 to treat solid tumors. In addition, the company develops vaccines for infectious diseases, such as SARS-CoV-2. It has collaborations with Novartis Institutes for BioMedical Research, Inc. To discover and develop novel TCR-T therapies; and Amgen Inc. to identify antigens recognized by T cells in patients with Crohn's disease using TargetScan, a proprietary target discovery platform. TScan Therapeutics, Inc. was incorporated in 2018 and is headquartered in Waltham, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Nebius Group: Up 385%, Analysts Say It’s Still a Bargain BigBear.ai: Why a 90% Rally Could Be Just the Start Chipotle: Too Spicy for Smart Money to Resist After Stock Split Plug Power’s 20% Surge Signals New Commercial Growth Era Will Oracle's Cloud and AI Deals Propel It to New Highs? Enovix Shares Hit 6-Month High; Long-Term Highs to Follow Tesla Stock Could Accelerate on New EV Tax Legislation SoundHound Rises as Short Sellers Exit and AI Demand Grows Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.